12 years of historical data (2013–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Editas Medicine, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $205M | $105M | $770M | $609M | $1.8B | $4.1B | $1.5B | $1.1B | $1.2B | $523M | — |
| Enterprise Value | $109M | $8M | $694M | $511M | $1.6B | $4.0B | $1.3B | $969M | $1.1B | $373M | — |
| P/E Ratio → | -0.76 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 6.35 | 3.24 | 9.85 | 30.90 | 70.28 | 45.29 | 72.09 | 33.55 | 90.26 | 86.39 | — |
| P/B Ratio | 1.35 | 0.78 | 2.20 | 1.69 | 3.24 | 10.44 | 5.64 | 4.54 | 5.96 | 3.88 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.25 | 8.89 | 25.95 | 63.35 | 44.04 | 61.90 | 30.34 | 82.02 | 61.57 | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Editas Medicine, Inc. earns an operating margin of -777.2%. Operating margins have expanded from -1146.3% to -777.2% over the past 3 years, signaling improving operational efficiency. A negative ROE of -98.1% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 92.2% | 67.9% | 80.2% | -74.1% | -372.0% | -183.9% | -505.8% | -841.3% | -1056.9% |
| Operating Margin | -777.2% | -777.2% | -216.6% | -1146.3% | -756.1% | -148.6% | -686.4% | -356.1% | -873.6% | -1605.6% | -2167.7% |
| Net Profit Margin | -733.7% | -733.7% | -196.1% | -1118.3% | -753.6% | -127.8% | -651.4% | -344.3% | -876.5% | -1605.5% | -4475.1% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -98.1% | -98.1% | -43.2% | -48.2% | -40.6% | -35.4% | -53.6% | -49.5% | -70.2% | -377.5% | — |
| ROA | -56.4% | -56.4% | -30.2% | -37.0% | -30.8% | -21.4% | -28.8% | -27.7% | -39.9% | -51.3% | -90.3% |
| ROIC | -120.8% | -120.8% | -47.2% | -53.0% | -44.1% | -60.7% | -113.0% | -74.6% | -227.0% | — | — |
| ROCE | -71.7% | -71.7% | -38.0% | -41.7% | -33.7% | -28.0% | -33.8% | -31.5% | -45.0% | -57.4% | -47.6% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $132M exceeds total debt of $35M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.26 | 0.26 | 0.14 | 0.12 | 0.05 | 0.07 | 0.11 | 0.14 | 0.16 | 0.26 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.72 | -0.22 | -0.27 | -0.32 | -0.29 | -0.80 | -0.43 | -0.54 | -1.12 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | -122.63 | — | -246.94 |
Net cash position: cash ($132M) exceeds total debt ($35M)
Short-term solvency ratios and asset-utilisation metrics
Editas Medicine, Inc.'s current ratio of 3.75x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 5.94x to 3.75x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.75 | 3.75 | 5.39 | 5.94 | 10.82 | 7.20 | 7.74 | 10.44 | 9.05 | 5.66 | 20.94 |
| Quick Ratio | 3.75 | 3.75 | 5.39 | 5.94 | 10.82 | 7.20 | 7.74 | 10.36 | 9.00 | 5.61 | 20.82 |
| Cash Ratio | 3.50 | 3.50 | 5.11 | 5.73 | 10.66 | 6.91 | 7.62 | 10.28 | 8.97 | 5.60 | 20.68 |
| Asset Turnover | — | 0.09 | 0.16 | 0.04 | 0.04 | 0.16 | 0.04 | 0.08 | 0.04 | 0.03 | 0.01 |
| Inventory Turnover | 31.07 | — | — | — | — | — | — | 31.07 | 44.61 | 34.28 | 24.16 |
| Days Sales Outstanding | — | 183.73 | 47.59 | 95.27 | 3.82 | 24.33 | 7.43 | 0.34 | 18.05 | 5.31 | 228.32 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Editas Medicine, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $82M | $76M | $69M | $68M | $59M | $50M | $47M | $40M | $32M | $36M |
Compare EDIT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| EDITYou | $205M | -0.8 | — | — | 100.0% | -777.2% | -98.1% | -120.8% | — |
| ALNY | $44B | 142.9 | 81.4 | 94.7 | 81.8% | 13.5% | 73.3% | 19.1% | 5.3 |
| IONS | $13B | -34.1 | — | — | 98.3% | -40.5% | -70.7% | -12.2% | — |
| ARWR | $9B | -5186.1 | 76.1 | 55.4 | 97.1% | 11.9% | -0.5% | 7.2% | 6.9 |
| CRSP | $6B | -9.3 | — | — | -2642.3% | -18933.6% | -30.2% | -27.4% | — |
| BEAM | $3B | -35.1 | — | — | 84.0% | -274.6% | -8.1% | -33.6% | — |
| WVE | $2B | -19.9 | — | — | 100.0% | -101.9% | -77.9% | — | — |
| RNA | $2B | -3.0 | — | — | 77.9% | -3977.3% | -44.0% | -42.8% | — |
| STOK | $2B | -22.1 | — | — | 100.0% | -277.3% | -45.8% | -206.8% | — |
| NTLA | $2B | -3.6 | — | — | — | — | -53.5% | — | — |
| ABUS | $895M | -12.3 | — | — | 100.0% | -1236.7% | -68.8% | -75.9% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 12 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how EDIT stacks up against sector leader Alnylam Pharmaceuticals, Inc..
Start ComparisonEditas Medicine, Inc.'s current P/E ratio is -0.8x. This places it at the 50th percentile of its historical range.
Editas Medicine, Inc.'s return on equity (ROE) is -98.1%. The historical average is -90.7%.
Based on historical data, Editas Medicine, Inc. is trading at a P/E of -0.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Editas Medicine, Inc. has 100.0% gross margin and -777.2% operating margin.